Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Liraglutide (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 02 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 08 Jun 2015 Planned number of patients changed from 80 to 20 as per ClinicalTrials.gov record.